🩺 The vaccine is the world’s first licensed vaccine for the prevention of chikungunya disease.
💉 The vaccine is a single-dose vaccine for individuals 18 years and older.
🌍 Valneva plans to sell the first doses in Canada in the fourth quarter of 2024.
🌐 The vaccine addresses an unmet medical need as millions of people travel to chikungunya-endemic countries each year.
🌡️ Valneva has also received approval from the US Food and Drug Administration and awaits approval from the European Medicines Agency.
Introduction:
Valneva SE has received approval from Health Canada for its chikungunya vaccine, IXCHIQ®, making it the first approved chikungunya vaccine in Canada. This follows its previous approval by the US Food and Drug Administration (FDA) and a recommendation for approval by the European Medicines Agency (EMA).
- Health Canada has approved Valneva’s chikungunya vaccine, IXCHIQ®, for the prevention of disease caused by the Chikungunya virus in individuals 18 years and older.
- IXCHIQ® is the only licensed chikungunya vaccine in the world and addresses the unmet medical need for a vaccine against this virus.
- More than 50 million North Americans, including approximately 7 million Canadians, travel to chikungunya-endemic countries each year, highlighting the importance of the vaccine.
- Valneva plans to sell the first doses of the vaccine in Canada in the fourth quarter of 2024.
- The company has also partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) and Instituto Butantan in Brazil to make the vaccine more accessible to low- and middle-income countries.
Conclusion:
The approval of Valneva’s chikungunya vaccine in Canada is a significant milestone in addressing the global burden of this disease. With millions of people traveling to chikungunya-endemic countries each year, the availability of a licensed vaccine can help reduce the spread and impact of this debilitating virus. Valneva’s partnership with CEPI and Instituto Butantan further demonstrates their commitment to making the vaccine accessible to vulnerable populations in low- and middle-income countries.
